Attrition Rates in Multiple Myeloma Treatment under Real World Conditions-An Analysis from the Austrian Myeloma Registry (AMR)

• Published in: Cancers Vol. 15; no. 3; p. 962
• Main Authors: Benda, Magdalena A, Ulmer, Hanno, Weger, Roman, Reimann, Patrick, Lang, Theresia, Pichler, Petra, Winder, Thomas, Hartmann, Bernd, Strassl, Irene, Krauth, Maria Theresa, Agis, Hermine, Sormann, Siegfried, Podar, Klaus, Willenbacher, Wolfgang, Willenbacher, Ella
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.02.2023; MDPI
• Subjects: Age; attrition rate; Autografts; Bortezomib; Cancer; Cardiovascular disease; Care and treatment; Cerebrovascular disease; Chemotherapy; Comorbidity; Dexamethasone; Diabetes; Evaluation; Heart failure; Induction therapy; Liver diseases; Multiple myeloma; Patient compliance; Patients; Remission; Remission (Medicine); Stem cell transplantation; treatment patterns; Variance analysis; Austria; attrition rate; multiple myeloma; treatment patterns
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15030962

Multiple myeloma (MM) is characterized by serial relapses, necessitating the application of sequential lines of therapy (LoT). Reports on attrition rates (ARs) vary widely. The present study analysed ARs from the Austrian Myeloma Registry. Attrition was defined as being either deceased, progressive without having received another LoT, or lack of follow-up for ≥5 years. A total of 571 patients diagnosed between January 2009 and August 2021 were included (median age: 72 years; median follow-up: 50.8 months). Some 507 patients received at least one LoT. Of the total, 43.6% underwent autologous stem cell transplantation (SCT, transplant eligible = TE)) with primarily VRd (Bortezomib/Lenalidomide/Dexamethasone) given as induction (26.5%), followed by lenalidomide maintenance in 55.7% of cases. Transplant-ineligible (NTE) patients were predominantly treated with Vd (Bortezomib/Dexamethasone, 21.6%), receiving maintenance in 27.1%. A total of 37.5% received a second LoT. ARs across one to five LoTs were 16.7-27%. Frontline induction/ SCT followed by maintenance reduced ARs associated with age and achievement of deep remission in the frontline. Deep remission prolongs follow-up and time-to-next-treatment (TTNT), while high-risk-cyctogenetics negatively affected these outcomes. Our results demonstrate considerably lower ARs for MM patients within the AMR data versus other healthcare systems. Young age and the achievement of significant remissions after optimal frontline therapy resulted in particularly low ARs. These promising results support a key role for the ease of drug access and reimbursement policies in governing long-term MM patient outcomes.